德甲剂量强度不会影响新诊断的多发性骨髓瘤的结果:二次SWOG分析
Rahul Banerjee1,2, Rachael Sexton3, Andrew J Cowan1,2
1Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.
Blood
|September 25, 2024
概括
在新诊断的多发性骨髓瘤 (NDMM) 诱导中,降低德克萨米他剂量是常见的,不会影响无进展或整体存活率. 需要进一步的研究来证实这些发现,给予德克萨米他.
科学领域:
- 血液学 血液学 血液学
- 临床瘤学临床瘤学
- 药理学 药理学是指药理学的学科.
背景情况:
- 德克萨米他对于新诊断的多发性骨髓瘤 (NDMM) 诱导至关重要,但会导致诸如高血糖等毒性.
- 以前的试验表明,较低的德克萨米他剂量可能是有效的,但剂量减少到每周低于40毫克需要进一步描述.
- 现代NDMM治疗方案涉及复杂的药物组合,需要重新评估德克萨米他的作用和最佳剂量.
研究的目的:
- 分析德甲剂量减少对NDMM患者无进展生存期 (PFS) 和整体生存期 (OS) 的影响.
- 为了比较接受全剂量德甲 (FD-DEX) 患者与降低剂量或停止服用德甲 (LD-DEX) 患者之间的结果.
- 在NDMM诱导中确定德克萨米他剂量的背景下PFS和OS的预测因子.
主要方法:
- 两项临床试验 (SWOG 0777和SWOG 1211) 的综合分析,涉及用lenalidomide和dexamethasone (Rd) 治疗的NDMM患者.
- 患者被分为FD-DEX或LD-DEX组,根据协议定义的德甲剂量对毒性进行调整.
- 使用多变量模型来评估德克萨米他剂量和其他因素对PFS和OS的影响.
主要成果:
- 在541名患者中,69% (373) 患者因毒性而接受LD-DEX.
- 在FD-DEX和LD-DEX组之间没有观察到PFS或OS的显著差异.
- 治疗组,年龄≥70岁和血小板衰竭被确定为PFS和OS的显著预测因素.
结论:
- 在NDMM诱导期间,即使在临床试验中,也经常会减少德克萨米他剂量.
- 在本分析中,降低德克萨梅他剂量并没有对PFS或OS产生负面影响.
- 有必要进行前性研究,以进一步调查在NDMM诱导中降低德甲剂量的安全性和有效性,考虑到其已知的毒性和不断变化的治疗环境.
更多相关视频
09:41An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
8.6K
05:32Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
Published on: January 7, 2019
6.8K
相关概念视频
Rational Dosage Regimen: Maintenance Dose and Loading Dose
4.0K
A rational dosage regimen considers a drug's pharmacokinetics, including its absorption, distribution, metabolism, and elimination from the body. By understanding these factors, the appropriate dosage can be determined, and the dosing schedule can be designed to achieve and maintain the desired therapeutic effect while minimizing adverse effects.
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
4.0K
Dose-Response Relationship: Potency and Efficacy
4.3K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
4.3K
Dosage Regimen: Fixed Dose
1.9K
Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
1.9K
Drug Dosage Regimen: Overview
3.5K
A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
3.5K
Myasthenia Gravis: Overview and Treatment
1.2K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.2K
